Cyclophosphamide pharmacogenomic variation in cancer treatment and its effect on bioactivation and pharmacokinetics
I El-Serafi, S Steele - Advances in Pharmacological and …, 2024 - Wiley Online Library
Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by cytochrome P450 (CYP)
2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its …
2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its …
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review
I Kulma, K Boonprasert, K Na-Bangchang - Cancer Chemotherapy and …, 2019 - Springer
Purpose Not all patients respond well to cancer chemotherapy. One of the most important
factors contributing to treatment response (efficacy and toxicity) is genetic determinant. The …
factors contributing to treatment response (efficacy and toxicity) is genetic determinant. The …
Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
Cyclophosphamide, an oxazaphosphorine prodrug is frequently used in treatment of
neuroblastoma, which is one of the most prevalent solid organ malignancies in infants and …
neuroblastoma, which is one of the most prevalent solid organ malignancies in infants and …
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell …
P Muñiz, C Andrés-Zayas, D Carbonell… - Frontiers in …, 2022 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for
patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an …
patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an …
Genetic polymorphism of GSTP-1 affects cyclophosphamide treatment of autoimmune diseases
P Hajdinák, M Szabó, E Kiss, L Veress, L Wunderlich… - Molecules, 2020 - mdpi.com
Cyclophosphamide is one of the most potent and reliable anti-cancer and
immunosuppressive drugs. In our study, 33 individuals with different autoimmune diseases …
immunosuppressive drugs. In our study, 33 individuals with different autoimmune diseases …
[HTML][HTML] FOXO3 polymorphisms influence the risk and prognosis of rhabdomyosarcoma in children
X Zhang, Y Sun, H Niu, P Tan, S Liu, X Liu… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children
and single nucleotide polymorphisms (SNPs) in certain genes influence risk of RMS …
and single nucleotide polymorphisms (SNPs) in certain genes influence risk of RMS …
[HTML][HTML] Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity
E Gambale, A Boddi, A Pasqui, DA Campanacci… - Cancer Treatment and …, 2022 - Elsevier
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are
unfortunately limited to a small subset of patients. Much of the inter-individual variability in …
unfortunately limited to a small subset of patients. Much of the inter-individual variability in …
[HTML][HTML] Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients
Objectives: Rhabdomyosarcoma (RMS) accounts for 50% of soft tissue sarcomas and 7% of
pediatric malignancies. Cyclophosphamide (CPA) is the cornerstone of therapy and is a …
pediatric malignancies. Cyclophosphamide (CPA) is the cornerstone of therapy and is a …
[HTML][HTML] Effects of genetic polymorphisms of CYP2B6 on the pharmacokinetics of bupropion and hydroxybupropion in healthy Chinese subjects
H Ma, W Zhang, X Yang, Y Zhang, S Wei… - … medical journal of …, 2018 - ncbi.nlm.nih.gov
Background Bupropion (BUP) is an antidepressant and its pharmacological activity is
mediated by its major metabolite, hydroxybupropion (HBUP). We investigated the effects of …
mediated by its major metabolite, hydroxybupropion (HBUP). We investigated the effects of …
Genetic polymorphisms effect on cyclophosphamide's tolerability and clinical efficacy in Egyptian patients with lupus nephritis
NN Abuelsoud, EMEL Khateeb - Pharmacogenetics and …, 2023 - journals.lww.com
Objectives Many studies were conducted to determine the association between genetic
polymorphisms in CYP2B6 c. 516G> T and cyclophosphamide (CYC) efficacy or toxicity, no …
polymorphisms in CYP2B6 c. 516G> T and cyclophosphamide (CYC) efficacy or toxicity, no …